How BCG Vaccine May Help Lower Blood Sugar in Type 1 Diabetes

BCG—bacille Calmette-Guérin—is not a new drug. This vaccine has protected millions of people from tuberculosis since its development over a century ago. More recently, it received FDA approval for use at higher doses in bladder cancer treatment. Now, researchers are investigating whether this well-tolerated vaccine can help people with Type 1 diabetes.

Over the past 15 years, multiple clinical trials have explored multi-dose BCG as an immunotherapy for autoimmune diabetes. The results have generated considerable interest: people receiving BCG showed stable reductions in HbA1c—the standard measure of average blood sugar—reaching near-normal levels compared to those who received placebo. This improvement has been sustained for at least 8 years in long-term follow-up.

One of the most striking findings is what BCG does not do: it does not restore the pancreas's ability to produce insulin. At baseline, participants had negligible pancreatic function, and this did not change after BCG treatment. Yet blood sugar control improved significantly. This paradox points to a different mechanism entirely.

Research suggests BCG works by reprogramming how immune cells generate energy. Specifically, it corrects defects in aerobic glycolysis—the process cells use to break down glucose—in lymphoid and myeloid immune cells. When these cells metabolize glucose more efficiently, they consume more of it from the bloodstream. The result: less glucose circulating in the blood, translating to better glycemic control.

This mechanism mirrors what researchers observe in tuberculosis granulomas, suggesting a shared principle in how BCG influences cellular metabolism across different disease contexts.

To confirm this metabolic shift, researchers used longitudinal PET/CT imaging—a specialized scanning technique that tracks how cells use glucose. The imaging data demonstrated that BCG-treated patients showed increased glucose uptake, meaning their immune cells were drawing more glucose from the bloodstream. This direct visualization supports the theory that metabolic reprogramming, not pancreatic recovery, drives the blood sugar improvements.

These findings represent a meaningful shift in how scientists think about treating Type 1 diabetes: instead of focusing solely on restoring the pancreas, this approach harnesses the immune system's own metabolic needs to reduce circulating glucose.

BCG's extensive safety history is a significant advantage. A century of global use against tuberculosis, combined with 36 years of FDA-approved use at higher doses for bladder cancer, has established a strong safety profile. This long track record provides a foundation of confidence as researchers continue to evaluate its potential in autoimmune diabetes.

While these findings are encouraging, ongoing research is needed to fully understand BCG's long-term effects, optimal dosing schedules, and whether the benefits hold across different patient populations. The sustained improvements documented over 8 years suggest promise, but additional studies will help clarify BCG's role in a comprehensive diabetes management strategy.

Source: Cells. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.